Marksans Pharma Ltd. — Board/Management Information 2020

Sep 3, 2020

·t· Marksans Pharma Ltd.

To,

National Stock Exchange of India Limited Exchange Plaza C-l, Block 'G'Bandra Kurla Complex, Bandra {E}, Mumbai - 40005l. Scrip Code: MARKSANS

To,

BSELimited

Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai - 400 OOL Scrip Code: 524404

Please be informed that the Board of Directors of the Company at its meeting held today i.e. 3[rd] September, 2020, has appointed Dr. Meena Rani Surana, subject to approval of the members at a general meeting, as an Independent Woman Director of the Company for a term of five (5) consecutive years with effect from 3[rd] September, 2020 not liable to retire by rotation.

The Company hereby confirms that Dr. Meena Rani Surana is not debarred by SEBI or any other authority.

Thanking You. Yours faithfully,

For Marksans Pharma Limited

ftaWJ~

Harshavardhan Panigrahi Company Secretary

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 224001 2000 • E-mail: info@marksanspharma.com www.marksanspharma.com

•• Marksans Pharma Ltd.

Dr. Meena Rani Surana is a pharma professional. She is Bachelor of Pharmacy and Ph.D in Pharmaceutics from Indian Institute of Technology, BOO, Varanasi, India and has done a Post Doctoral Fellowship in Pharmaceutics from Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA.

She has about 27 years of experience ill pharmaceutical regulatory affairs, quality assurance, formulation and pre-formulation.

She has experience of ANDA filings with US FDA for more than 100 drug products and familiarity with CMC section review of INDs and NDAs of several drug products. She has extensive experience & familiarity with eCTD format & software requirements, SPL Labeling, regulatory requirements of pharmaceutical industry, FDA/ICH/EMEA guidelines, CDER guidelines, Code of Federal Regulations (21 CFR part 314, 201, 210 & 211 etc.), Drug approval process for ANDA/IND/NDA, DMF filing, handling of all drug products post-approval activities, SUPAC guidelines/requirements for IRJMR Drug Products, cGMP/cGLP/Compliance requirements, promotional labeling and marketing requirements, requirements & handling of controlled substances (DEA requirements), Pharmacovigilance requirements for approved & GMP products, etc.

She has also experience, knowledge & involvement in preparation of SOPs, policies & procedures, qualification procedures (equipment, raw materials, contract laboratories, CROs), investigation reports (complaints/OOS/deviations/Incidents etc.) cleaning validation, manufacturing, packaging & warehousing procedures in order to comply GMP requirements at firm, technical reports & protocols, ensuring cGMP training, conducting QA compliance internal audits, ensuring safety regulations etc.

Dr. Meena Rani Surana has published 12 research articles in reputed international journals and presented research work at several conferences. She is reviewer of internationally renowned pharmaceutical journals, including Journal of Pharmacy & Pharmaceutical Sciences (JPPS), AAPS Pharm SciTech and Pharmaceutical Research. She has many awards and honours to her credit.

She is affiliated to American Association of Pharmaceutical Scientists and Indian Pharmaceutical Congress.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 224001 2000 • E-mail: info@marksanspharma.com www.marksanspharma.com